# Obsidian Therapeutics Inc. (OBX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $13.23, market value $817 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Obsidian Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Free-cash-flow yield: -11.1%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 37.8%**. 37.8% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.

## Growth
- **EPS growth (1 yr): -21.1%**. Earnings per share fell 21.1%.

## Financial health
- **Current ratio: 5.31** (quick 5.31). Current assets cover the next year's liabilities 5.31 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Obsidian Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **From 52-week high: -73.5%** (14.8% above the low). Trading 74% below its 52-week high, deep in a drawdown.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 4.61** (volatility 196%). Beta of 4.61 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=OBX · Page: https://foliofundamentals.com/stocks/obx

Not investment advice.